| Identification | Back Directory | [Name]
Butanamide, 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N,3-dihydroxy-, (2R,3S)- | [CAS]
287406-12-6 | [Synonyms]
Butanamide, 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N,3-dihydroxy-, (2R,3S)- | [Molecular Formula]
C14H18N2O6S | [MOL File]
287406-12-6.mol | [Molecular Weight]
342.37 |
| Chemical Properties | Back Directory | [density ]
1.380±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 2mg/mL, clear | [form ]
powder | [pka]
8.93±0.40(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Biological Activity]
PF-05480090 (PF-5480090; TMI-2) is an orally activepotent TACE (ADAM17) inhibitor (IC50 = 2 nM) with good selectivity over ADAM10 (IC50 = 1.09 μM)MMP-1/7 (IC50 = 2.47/0.96 μM) and MMP-8/9/13/14 (IC50 =35/ 777/96/582 nM). TMI-2 inhibits LPS-induced TNF production in cultrues (RAW/THP-1 IC50 = 200/430 nM)ex vivo (human whole blood IC50 = 1 μM) and in vivo (ED50 = 3 mg/kg; TMI-2 p.o. 1 hr prior to 40 ng LPS/mouse i.v.). TMI-2 is efficacious in a r at model of adjuvant-induced arthritis (AIA; 30 and 100 mg/kg p.o. b.i.d.) and a murine model of collagen-induced arthritis (CIA; 100 mg/kg p.o. b.i.d.). |
|
| Company Name: |
Merck KGaA
|
| Telephone: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|